Takeda Pharmaceutical Co Ltd
4502.T- Latest Trade
- trading lower4,078JPY
- -12
- 0.29%
- As of Feb 1 2023. Values delayed up to 15 minutes
- Day Range
- 4,076.00 - 4,102.00
- 52-Week Range
- 3,250.00 - 4,238.00
- Previous Close
- 4,090.00
- Open
- 4,090.00
- Volume
- 2,045,100.00
- 3 Month Average Trading Volume
- 91.87
- Shares Out (Mil)
- 1,554.52
- Market Cap
- 6,471,570.00
- Forward P/E
- 17.24
- Dividend Yield
- 4.40
Key Statistics
2.5 mean rating - 16 analysts
- P/E Excl. Extra Items (TTM)
- 29.90
- Price To Sales (TTM)
- 1.73
- Price To Book (Quarterly)
- 0.95
- Price To Cash Flow (Per Share TTM)
- 7.71
- Total Debt/Total Equity (Quarterly)
- 70.56
- Long Term Debt/Equity (Quarterly)
- 62.10
- Return On Investment (TTM)
- 1.87
- Return On Equity (TTM)
- 1.57
2021 (millions USD)
About Takeda Pharmaceutical Co Ltd (4502.T)
Company Information
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Address
4F, 2-1-1, Nihombashihon-choCHUO-KU, TKY
103-8668
Japan
Industry
Biotechnology & Drugs
Executive Leadership
- Masami Iijima
- Chairman of Board of Directors, Independent Director
- Christophe Weber
- President, Chief Executive Officer, Representative Director
- Costa Saroukos
- Chief Financial Officer, Director
- Andrew S. Plump
- President of Research & Development, Vice President of Subsidiary, Director
- Masato Iwasaki
- Representative Director
- Olivier Bohuon
- Independent Director
- Jean-Luc Butel
- Independent Director
- Ian Clark
- Independent Director
- Yoshiaki Fujimori
- Independent Director
- Steven Gillis
- Independent Director
- Koji Hatsukawa
- Independent Director
- Emiko Higashi
- Independent Director
- John M. Maraganore
- Independent Director
- Michel Orsinger
- Independent Director
- Kimberly A. Reed
- Independent Director
Latest News
- BusinessKalVista shares sink after ending drug trial for hereditary disease
KalVista Pharmaceuticals Inc said on Tuesday it has ended a mid-stage study for its drug to prevent recurrent swelling attacks in people with hereditary angioedema due to safety concerns, sending its shares down more than 40%.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,926.80 | 0.14% |
| Copper | 786.50 | 0.14% |
| Brent Crude Oil | 85.73 | 0.32% |
| CBOT Soybeans | 1,538.00 | -- |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,076.60 | 1.46% |
| Euro STOXX 50 | 4,163.45 | -- |
| FTSE 100 | 7,771.70 | 0.17% |
| Nikkei 225 | 27,362.49 | 0.13% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes